World-first coeliac disease vaccine enters phase 2 trials in Melbourne

30 October 2018
Key Researchers
Laboratory Head
Dr Jason Tye-Din
Head of coeliac research at the Institute Dr Jason Tye-Din
is leading the Melbourne phase 2 trial of immune therapy
A coeliac disease vaccine that aims to protect patients from the harmful effects of gluten has entered phase 2 clinical trials in Melbourne.
  • [June 2019 update below]

Following the commencement of global trials led by US-based pharmaceutical company ImmusanT Inc., the Australian trials will commence at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne and then roll out in Perth, Adelaide, Brisbane, Mackay and the Sunshine Coast. 

Led by the Walter and Eliza Hall Institute’s head of coeliac research and gastroenterologist at the Royal Melbourne Hospital Dr Jason Tye-Din, the Melbourne trial of Nexvax2® (RESET CeD) is now recruiting for patients with coeliac disease.

Coeliac disease is caused by an immune reaction to the gluten protein found in wheat, rye and barley. The autoimmune disease is becoming increasingly prevalent, and is estimated to currently affect one in 70 Australians and 1.4 per cent of the global population.

Dr Tye-Din said volunteer participation was crucial to the success of the trials. “The vaccine is designed to target the 90 per cent of coeliac disease patients with the HLA-DQ2 genetic form of disease,” he said.

Dr Tye-Din said he was very excited about the commencement of phase 2 trials because of the therapy’s potential for one day enabling patients to safely have gluten in their diet. “A successful therapy that can restore normal gluten tolerance would revolutionise coeliac disease management.

Nexvax2® is designed to restore what is lost in coeliac disease – the ability of the immune system to tolerate gluten.

President of Coeliac Australia Mr Michael Bell said the organisation’s members and many thousands of Australians with coeliac disease had been looking forward to the announcement of phase 2 trials.

“Many have been following the development of Nexvax2 for more than a decade and are hopeful the trials will take us one step closer to an effective treatment for coeliac disease,” Mr Bell said.

Building on Institute research

Dr Tye-Din has been leading the way in understanding what triggers coeliac disease in a combined effort involving patients, clinicians and scientists for more than a decade.

Initiated by Dr Bob Anderson, now chief scientific officer for ImmusanT Inc., and Dr Tye-Din in 2003, the Institute’s coeliac research program identified the toxic parts – or peptides – of gluten that led to the design of the targeted immune treatment and subsequent phase 1 trials undertaken in Melbourne.

“The results from national and international phase 1 trials showed that the therapy was safe and well tolerated even at the highest doses used, and also showed an intended biological effect on the immune system in patients with coeliac disease. The phase 2 trials build on the data from earlier studies and it is great that Australia is still playing a pivotal role in this work,” Dr Tye-Din said.

More information

June 2019 update: US based biotechnology company ImmusanT Inc has announced it will discontinue its Phase 2 clinical trials of Nexvax2®. An interim analysis showed the drug did not provide statistically significant symptom protection from gluten when compared with placebo results. Nexvax2® was found to be safe with no concerning safety issues identified during the study.

Media enquiries

M: +61 475 751 811
E: communityrelations@wehi.edu.au

WEHI Authors
Laboratory Head
Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Winter 2024
View the current issue